Most Common Types of Type 2 Diabetes Medications GLP-1 and dual GLP-1/GIP receptor agonists SGLT2 inhibitors Metformin DPP-4 inhibitors Thiazolidinediones (TZDs) Sulfonylureas Alpha-glucosidase inhibitors Meglitinides Some Type 2 diabetes medications may cause serious side effects. For example, rare...
SGLT-2 Inhibitors: Do the Benefits Outweigh the RisksAnne L Peters, MD
A new study provides the first comprehensive safety profile of sodium-glucose cotransporter 2 (SGLT2) inhibitors in US patients withchronic kidney disease (CKD)andtype 2 diabetesreceiving routine care and suggests that the benefits outweigh the risks. Starting therapy with an SGLT2 inhibitor versus ...
Beneficial effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors demonstrated in heart failure (HF) and chronic kidney disease (CKD) support their expanded role beyond treatment of type 2 diabetes mellitus (T2DM). At the 5~th Annual Meeting of Endocrinology, Diabetes & Metabolism Hong Kong...
pressure, weight, and body mass index in this population with an acceptable safety profile. The current evidence supports the potential role of SGLT2 inhibitors as primary prevention in individuals without diabetes, HF, and/or CKD. This review may shed light on the use of SGLT2 inhibitors in ...
SGLT-2 inhibitors are a relatively new class of diabetes drugs that have shown many benefits for people with type 2 diabetes who have not responded well to previous interventions, including diet changes and metformin. Patients who take this medication se
Sodium-glucose cotransporter-2 (SGLT2) inhibitors are a class I guideline-directed medical therapy (GDMT) for patients with heart failure with reduced ejection fraction (HFrEF).1, 2, 3, 4 In both the DAPA-HF (Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure) and the EMPEROR...
Sodium-glucose cotransporter 2 (SGLT2) inhibitors are the newest class of antihyperglycemic agents. They are increasingly being prescribed in the outpatient diabetic population. In this review, we examine the risks and benefits of continuation and initiation of SGLT2 inhibitors in the inpatient setting...
Cardiovascular Outcomes and Risks After Initiation of a Sodium Glucose Co-Transporter 2 Inhibitor: Results From the EASEL Population-Based Cohort Study Background : Clinical trials have shown cardiovascular benefits and potential risks from sodium glucose co-transporter 2 inhibitors (SGLT2i). Trials may...
Despite the superior cardiorenal benefits of sodium/glucose cotransporter-2 inhibitors (SGLT-2i) and GLP-1RAs [75, 76], DPP-4i remained a common choice among these three classes of anti-diabetic agents, with more patients using DPP-4i than the other two [77]. In-class differences were ...